Risk of Recurrent Bleeding Events in Nonvalvular Atrial Fibrillation Treated with Vitamin K Antagonists: A Clinical Practice Research Datalink Study

Abstract

Background There is little evidence on how the occurrence of a bleed in individuals on vitamin K antagonists (VKAs) impacts the risk of subsequent bleeds, and thromboembolic and ischemic events. Such information would help to inform treatment decisions following bleeds.

Objective To estimate the impact of bleeding events on the risk of subsequent bleeds, venous thromboembolism (VTE), stroke, and myocardial infarction (MI) among patients initiating VKA treatment for new-onset nonvalvular atrial fibrillation (NVAF).

Methods We conducted an observational cohort study using a linked Clinical Practice Research Datalink—Hospital Episode Statistics dataset. Among a cohort of individuals with NVAF, the risk of clinically relevant bleeding, VTE, stroke, and MI was compared between the period prior to the first bleed and the periods following each subsequent bleed. The rate and cost of general practitioner (GP) consultations, prescriptions, and hospitalizations were also compared across these periods.

Results The risk of clinically relevant bleeding events was observed to be elevated at least twofold in all periods following the first bleeding event. The risk of VTE, stroke, and MI was not found to differ according to the number of clinically relevant bleeding events. The rate and cost of GP consultations, GP prescriptions, and hospitalizations were increased in all periods relative to the period prior to the first bleed.

Conclusions The doubling in the risk of bleeding following the first bleed, taken alongside the stable risk of MI, VTE, and stroke, suggests that the risk–benefit balance for VKA treatment should be reconsidered following the first clinically relevant bleed.

Keywords

VKA - bleeding - atrial fibrillation - risk

• References

• 1 Fuster V, Rydén LE, Cannom DS. , et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114 (07) e257-e354
• 2 Friberg J, Buch P, Scharling H, Gadsbphioll N, Jensen GB. Rising rates of hospital admissions for atrial fibrillation. Epidemiology 2003; 14 (06) 666-672
• 3 Miyasaka Y, Barnes ME, Gersh BJ. , et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006; 114 (02) 119-125
• 4 Hearth Rhythm Society (HRS). Atrial fibrillation (AFib) awareness. Available at: http://www.hrsonline.org/News/Atrial-Fibrillation-AFib-Awareness#axzz2mAMgzGsO . Accessed September 13, 2019
• 5 Atrial Fibrillation Association. The AF Report—atrial fibrillation: preventing a stroke crisis. 2012 . Available at: http://www.preventaf-strokecrisis.org/files/files/The%20AF%20Report%2014%20April%202012.pdf
• 6 Banach M, Mariscalco G, Ugurlucan M, Mikhailidis DP, Barylski M, Rysz J. The significance of preoperative atrial fibrillation in patients undergoing cardiac surgery: preoperative atrial fibrillation—still underestimated opponent. Europace 2008; 10 (11) 1266-1270
• 7 Camm AJ, Kirchhof P, Lip GY. , et al; European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31 (19) 2369-2429
• 8 January CT, Wann LS, Alpert JS. , et al; ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014; 130 (23) 2071-2104
• 9 Roskell NS, Samuel M, Noack H, Monz BU. Major bleeding in patients with atrial fibrillation receiving vitamin K antagonists: a systematic review of randomized and observational studies. Europace 2013; 15 (06) 787-797
• 10 Gallagher AM, Rietbrock S, Plumb J, van Staa TP. Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis?. J Thromb Haemost 2008; 6 (09) 1500-1506
• 11 Ruff CT, Giugliano RP, Braunwald E. , et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383 (9921): 955-962
• 12 Oktay E. Will NOACs become the new standard of care in anticoagulation therapy?. International Journal of the Cardiovascular Academy 2015; 1 (01) 1-4
• 13 Staerk L, Fosbøl EL, Gadsbøll K. , et al. Non-vitamin K antagonist oral anticoagulation usage according to age among patients with atrial fibrillation: Temporal trends 2011-2015 in Denmark. Sci Rep 2016; 6 (01) 31477
• 14 Goldstein JN, Greenberg SM. Should anticoagulation be resumed after intracerebral hemorrhage?. Cleve Clin J Med 2010; 77 (11) 791-799
• 15 Herrett E, Gallagher AM, Bhaskaran K. , et al. Data Resource Profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol 2015; 44 (03) 827-836
• 16 Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 2010; 69 (01) 4-14
• 17 Schulman S, Kearon C. ; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3 (04) 692-694
• 18 Olesen JB, Lip GYH, Hansen ML. , et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 2011; 342: d124
• 19 Global RPH. HAS-BLED bleeding risk score. Available at: http://www.globalrph.com/has-bled-score.htm . Accessed September 13, 2019
• 20 NHS reference costs. Available at: https://www.gov.uk/government/collections/nhs-reference-costs#published-reference-costs . Accessed January 1, 2014
• 21 Personal Social Services Research Unit (PSSRU). Available at: http://www.pssru.ac.uk . Accessed January 1, 2014
• 22 NICE. Atrial fibrillation: management. Available at: https://www.nice.org.uk/guidance/cg180/ . Accessed March 29, 2019
• 23 Halvorsen S, Storey RF, Rocca B. , et al; ESC Working Group on Thrombosis. Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis. Eur Heart J 2017; 38 (19) 1455-1462
• 24 Proietti M, Romiti GF, Romanazzi I. , et al. Restarting oral anticoagulant therapy after major bleeding in atrial fibrillation: a systematic review and meta-analysis. Int J Cardiol 2018; 261: 84-91
• 25 Korompoki E, Filippidis FT, Nielsen PB. , et al. Long-term antithrombotic treatment in intracranial hemorrhage survivors with atrial fibrillation. Neurology 2017; 89 (07) 687-696
• 26 van Nieuwenhuizen KM, van der Worp HB, Algra A. , et al; APACHE-AF Investigators. Apixaban versus Antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intraCerebral HaEmorrhage in patients with Atrial Fibrillation (APACHE-AF): study protocol for a randomised controlled trial. Trials 2015; 16 (01) 393